Combination therapy with IFNα and IL-2 has been reported to enhance the cytotoxic activities of NK cells in patients with advanced RCC (16) and NK cells have been shown to be necessary for anti-tumor activities in RCC patients treated with cytokines (17). This evidence concerns the gene IFNA1 and neoplasm.